Your session is about to expire
← Back to Search
Repotrectinib + Chemotherapy for Cancer
Study Summary
This trial will test the safety of repotrectinib in combination with chemo in children & young adults with advanced solid tumors. The goal is to find the highest dose that causes few side effects. They'll also evaluate whether it's an effective treatment & study how the body processes the drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition meets the specific criteria for this study.I have recovered from side effects of my previous cancer treatments.My brain tumor does not affect my daily activities much.I have waited the required time since my last therapy before starting a new one.My condition worsened while I was being treated with irinotecan/temozolomide.I meet the age requirement for the study phase.My neuroblastoma is only in my bone marrow and confirmed by a specific test.I am currently being treated for an active infection.I do not have severe health or mental conditions that could make this study unsafe for me.My study phase determines my tissue analysis needs.I have a known bone marrow disease.I have a stomach or intestine condition that affects how drugs are absorbed.I am using or might need strong CYP3A4 affecting drugs.I have not had major surgery in the last 2 weeks.My heart's electrical cycle is within normal range for my gender.My cancer can be measured or seen on tests.I meet the time requirements after my specific treatments.I have Gilbert Syndrome or Crigler-Najjar.My condition did not improve after standard treatment.I have severe nerve pain or numbness.My blood counts and organ functions meet the required levels.I haven't had radiation treatment in the last two weeks.I am following pregnancy prevention measures as a woman able to have children.
- Group 1: Repotrectinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Who might this trial be most beneficial for?
"This clinical trial is for children aged 1-25 who have cancer that has progressed. They are looking to recruit 50 participants."
For what purpose is Repotrectinib most commonly prescribed?
"Repotrectinib is most often used to treat melanoma, but it can also be given to patients with other conditions like soft tissue sarcoma (sts), primary central nervous system lymphoma (pcnsl), and malignant neoplasms."
Could you explain the age requirement for participation in this research?
"This clinical trial is only for individuals aged 1 to 25. Out of the 381 trials available for people under 18 and 2790 trials available for those over 65, this one is most applicable to you."
How many guinea pigs are needed for this scientific experiment?
"That is accurate. The clinical trial in question, as indicated by information on clinicaltrials.gov, is still looking for participants. This particular trial was posted on 8/9/2021 and edited more recently on 8/22/20222. They are recruiting 50 individuals from 1 site total."
Are investigators still enrolling volunteers for this research project?
"Yes, the website clinicaltrials.gov has information indicating that this medical trial is recruiting patients right now. The original posting was on August 9th, 2021 with the most recent update occurring on August 22nd, 2022. They are looking to enroll 50 individuals at a single location."
What are the previous findings of research projects involving Repotrectinib?
"As of now, 463 clinical trials concerning Repotrectinib are ongoing with 77 being in Phase 3. While the majority of studies related to Repotrectinib originate from Boston, Massachusetts, there are 12930 locations conducting these medical trials."
Share this study with friends
Copy Link
Messenger